Abstract
Aims: Raloxifene treatment of osteoporotic fractures is clinically effective, but economic evidence in support of raloxifene reimbursement is lacking in the People’s Republic of China. We aimed at evaluating the cost-effectiveness of raloxifene in the treatment of osteoporotic fractures using an osteoporosis health economic model. We also assessed the impact of medica tion persistence and adherence on clinical outcomes and cost-effectiveness of raloxifene. Methods: We used a previously developed and validated osteoporosis state-transition microsimu lation model to compare treatment with raloxifene with current practices of osteoporotic fracture treatment (conventional treatment) from the health care payer’s perspective. A Monte Carlo probabilistic sensitivity analysis with microsimulations was conducted. The impact of medica tion persistence and adherence on clinical outcomes and the cost-effectiveness of raloxifene was addressed in sensitivity analyses. The simulated patients used in the model’s initial state were 65-year-old postmenopausal Chinese women with osteoporosis (but without previous fractures), simulated using a 1-year cycle length until all patients had died. Costs were presented in 2015 US dollars (USD), and costs and effectiveness were discounted at 3% annually. The willingness to-pay threshold was set at USD 20,000 per quality-adjusted life year (QALY) gained. Results: Treatment with raloxifene improved clinical effectiveness by 0.006 QALY, with additional costs of USD 221 compared with conventional treatment. The incremental cost effectiveness ratio was USD 36,891 per QALY gained. The cost-effectiveness decision did not change in most of the one-way sensitivity analyses. With full raloxifene persistence and adherence, average effectiveness improved compared with the real-world scenario, and the incremental cost effectiveness ratio was USD 40,948 per QALY gained compared with conventional treatment. Conclusion: Given the willingness-to-pay threshold, raloxifene treatment was not cost-effective for treatment of osteoporotic fractures in postmenopausal Chinese women. Medication persis tence and adherence had a great impact on clinical and cost-effectiveness, and therefore should be incorporated in future pharmacoeconomic studies of osteoporosis interventions.
| Language | English |
|---|---|
| Pages | 415-423 |
| Number of pages | 9 |
| Journal | Patient Preference and Adherence |
| Volume | 10 |
| DOIs | |
| Publication status | Published - 29 Mar 2016 |
| Externally published | Yes |
Fingerprint
Bibliographical note
Copyright 2016 Chen et al. This work is published and licensed by Dove Medical Press Limited. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.Keywords
- Adherence
- Chinese
- Cost-effectiveness
- Persistence
- Postmenopausal osteoporosis
Cite this
}
Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women : impact of medication persistence and adherence. / Chen, Mingsheng; Si, Lei; Winzenberg, Tania M.; Gu, Jieruo; Jiang, Qicheng; Palmer, Andrew J.
In: Patient Preference and Adherence, Vol. 10, 29.03.2016, p. 415-423.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women
T2 - Patient Preference and Adherence
AU - Chen, Mingsheng
AU - Si, Lei
AU - Winzenberg, Tania M.
AU - Gu, Jieruo
AU - Jiang, Qicheng
AU - Palmer, Andrew J.
N1 - Copyright 2016 Chen et al. This work is published and licensed by Dove Medical Press Limited. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2016/3/29
Y1 - 2016/3/29
N2 - Aims: Raloxifene treatment of osteoporotic fractures is clinically effective, but economic evidence in support of raloxifene reimbursement is lacking in the People’s Republic of China. We aimed at evaluating the cost-effectiveness of raloxifene in the treatment of osteoporotic fractures using an osteoporosis health economic model. We also assessed the impact of medica tion persistence and adherence on clinical outcomes and cost-effectiveness of raloxifene. Methods: We used a previously developed and validated osteoporosis state-transition microsimu lation model to compare treatment with raloxifene with current practices of osteoporotic fracture treatment (conventional treatment) from the health care payer’s perspective. A Monte Carlo probabilistic sensitivity analysis with microsimulations was conducted. The impact of medica tion persistence and adherence on clinical outcomes and the cost-effectiveness of raloxifene was addressed in sensitivity analyses. The simulated patients used in the model’s initial state were 65-year-old postmenopausal Chinese women with osteoporosis (but without previous fractures), simulated using a 1-year cycle length until all patients had died. Costs were presented in 2015 US dollars (USD), and costs and effectiveness were discounted at 3% annually. The willingness to-pay threshold was set at USD 20,000 per quality-adjusted life year (QALY) gained. Results: Treatment with raloxifene improved clinical effectiveness by 0.006 QALY, with additional costs of USD 221 compared with conventional treatment. The incremental cost effectiveness ratio was USD 36,891 per QALY gained. The cost-effectiveness decision did not change in most of the one-way sensitivity analyses. With full raloxifene persistence and adherence, average effectiveness improved compared with the real-world scenario, and the incremental cost effectiveness ratio was USD 40,948 per QALY gained compared with conventional treatment. Conclusion: Given the willingness-to-pay threshold, raloxifene treatment was not cost-effective for treatment of osteoporotic fractures in postmenopausal Chinese women. Medication persis tence and adherence had a great impact on clinical and cost-effectiveness, and therefore should be incorporated in future pharmacoeconomic studies of osteoporosis interventions.
AB - Aims: Raloxifene treatment of osteoporotic fractures is clinically effective, but economic evidence in support of raloxifene reimbursement is lacking in the People’s Republic of China. We aimed at evaluating the cost-effectiveness of raloxifene in the treatment of osteoporotic fractures using an osteoporosis health economic model. We also assessed the impact of medica tion persistence and adherence on clinical outcomes and cost-effectiveness of raloxifene. Methods: We used a previously developed and validated osteoporosis state-transition microsimu lation model to compare treatment with raloxifene with current practices of osteoporotic fracture treatment (conventional treatment) from the health care payer’s perspective. A Monte Carlo probabilistic sensitivity analysis with microsimulations was conducted. The impact of medica tion persistence and adherence on clinical outcomes and the cost-effectiveness of raloxifene was addressed in sensitivity analyses. The simulated patients used in the model’s initial state were 65-year-old postmenopausal Chinese women with osteoporosis (but without previous fractures), simulated using a 1-year cycle length until all patients had died. Costs were presented in 2015 US dollars (USD), and costs and effectiveness were discounted at 3% annually. The willingness to-pay threshold was set at USD 20,000 per quality-adjusted life year (QALY) gained. Results: Treatment with raloxifene improved clinical effectiveness by 0.006 QALY, with additional costs of USD 221 compared with conventional treatment. The incremental cost effectiveness ratio was USD 36,891 per QALY gained. The cost-effectiveness decision did not change in most of the one-way sensitivity analyses. With full raloxifene persistence and adherence, average effectiveness improved compared with the real-world scenario, and the incremental cost effectiveness ratio was USD 40,948 per QALY gained compared with conventional treatment. Conclusion: Given the willingness-to-pay threshold, raloxifene treatment was not cost-effective for treatment of osteoporotic fractures in postmenopausal Chinese women. Medication persis tence and adherence had a great impact on clinical and cost-effectiveness, and therefore should be incorporated in future pharmacoeconomic studies of osteoporosis interventions.
KW - Adherence
KW - Chinese
KW - Cost-effectiveness
KW - Persistence
KW - Postmenopausal osteoporosis
UR - http://www.scopus.com/inward/record.url?scp=84962050432&partnerID=8YFLogxK
U2 - 10.2147/PPA.S100175
DO - 10.2147/PPA.S100175
M3 - Article
VL - 10
SP - 415
EP - 423
JO - Patient Preference and Adherence
JF - Patient Preference and Adherence
SN - 1177-889X
ER -